Related Experiment Video

Updated: May 22, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis

Hetal B Patel1, Kristin N Kornerup, Andre' L F Sampaio

  • 1William Harvey Research Institute, Barts and The London School of Medicine, London UK.

Annals of the Rheumatic Diseases
|May 8, 2012
PubMed
Abstract

Insights

The annexin A1 (AnxA1) pathway is crucial for glucocorticoid effectiveness in inflammatory arthritis. A modified AnxA1, SuperAnxA1, shows potential for new anti-inflammatory arthritis treatments.

Area of Science:

  • Immunology
  • Pharmacology
  • Molecular Biology

Background:

  • Glucocorticoids are widely used to treat inflammatory arthritis.
  • The endogenous annexin A1 (AnxA1) pathway's role in glucocorticoid efficacy is not fully understood.

Purpose of the Study:

  • To investigate the role of the AnxA1 pathway in inflammatory arthritis.
  • To determine the effect of glucocorticoids and AnxA1 on arthritis.
  • To explore potential therapeutic applications of AnxA1.

Main Methods:

  • Analysis of AnxA1 pathway components in mouse ankle joints using real-time PCR and immunohistochemistry.
  • Induction of inflammatory arthritis in wild-type and AnxA1 knockout mice.
  • Treatment with dexamethasone (Dex), recombinant AnxA1, or SuperAnxA1.

Main Results:

  • AnxA1 pathway components were detected in joints and increased during arthritis.
  • AnxA1 knockout mice showed attenuated dexamethasone antiarthritic effects.
  • SuperAnxA1 accelerated the resolution of arthritis in treated mice.

Conclusions:

  • AnxA1 is essential for dexamethasone's therapeutic efficacy in inflammatory arthritis.
  • SuperAnxA1 can partially mimic AnxA1's effects and may be a basis for new arthritis therapies.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...